1BD.F BIO-WORKS TECHN. AB
- Market cap
- EUR 25.3M
- P/E
- -
- P/B
- 6.24x
- ROE
- -16.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 1BD.F undervalued?
Graham numberThe Graham number of BIO-WORKS TECHN. AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BIO-WORKS TECHN. AB fundamental analysis
No fundamental analysis for BIO-WORKS TECHN. AB yet.
BIO-WORKS TECHN. AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BIO-WORKS TECHN. AB
Bio-Works Technologies AB (publ), together with its subsidiaries, engages in the manufactures and sale of chromatography resins for the purification of biopharmaceuticals in Sweden. The company offers affinity and activated resin, hydrophobic interaction chromatography (HIC) resins, GoBio Mini and GoBio prepacked columns, ion exchange chromatography (IEX) resin, immobilized metal-ion affinity chromatography (IMAC) resin, size exclusion chromatography (SEC) resins, HTPD forma…
Full company profileBIO-WORKS TECHN. AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BIO-WORKS TECHN. AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 41.3M | 43.9M | 25.5M | 62.5M | 78.6M |
| Gross Profit | 28.8M | 26.8M | 20.0M | 47.8M | 59.4M |
| Operating Income | -47.1M | -57.5M | -38.8M | -18.1M | -9.30M |
| EBITDA | -44.2M | -54.1M | -36.8M | -16.7M | -8.78M |
| Net Income | -45.0M | -56.8M | -37.4M | -15.2M | -7.38M |
| EPS | -0.91 | -1.04 | -0.48 | -0.16 | -0.07 |
| Balance Sheet | |||||
| Total Assets | 91.6M | 62.2M | 52.5M | 70.8M | 70.7M |
| Total Liabilities | 23.9M | 18.1M | 7.91M | 21.6M | 24.9M |
| Shareholders' Equity | 67.7M | 44.0M | 44.6M | 49.2M | 45.7M |
| Cash & Short-term Investments | 65.9M | 39.4M | 34.3M | 34.9M | 43.8M |
| Cash Flow | |||||
| Operating Cash Flow | -39.9M | -59.0M | -43.2M | -18.8M | 10.5M |
| Capital Expenditure | 1.12M | 860K | 8.00K | 404K | 1.37M |
| Free Cash Flow | -41.0M | -59.9M | -43.2M | -19.2M | 9.12M |
| Ratios | |||||
| ROE | -66.4% | -129.0% | -83.8% | -31.0% | -16.2% |
| ROA | -49.1% | -91.4% | -71.2% | -21.5% | -10.4% |
| Net Profit Margin | -108.8% | -129.4% | -146.7% | -24.4% | -9.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BIO-WORKS TECHN. AB dividends
BIO-WORKS TECHN. AB has not paid dividends in the last 4 fiscal years.
Who owns BIO-WORKS TECHN. AB
- Insiders 50.44%
- Institutions 11.93%
- Public & others 37.63%
- Shares outstanding 100M
- Free float 46.8M
BIO-WORKS TECHN. AB company profile
- Company name
- BIO-WORKS TECHN. AB
- Ticker
- 1BD.F
- ISIN
- SE0007387089
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 32
- Fiscal year end
- December
- Address
- Virdings allé 18, Uppsala, Sweden, 754 50
- Phone
- 46 8 56 26 74 30
- Website
- bio-works.com
About BIO-WORKS TECHN. AB
Bio-Works Technologies AB (publ), together with its subsidiaries, engages in the manufactures and sale of chromatography resins for the purification of biopharmaceuticals in Sweden. The company offers affinity and activated resin, hydrophobic interaction chromatography (HIC) resins, GoBio Mini and GoBio prepacked columns, ion exchange chromatography (IEX) resin, immobilized metal-ion affinity chromatography (IMAC) resin, size exclusion chromatography (SEC) resins, HTPD formats, screening kits, and desalting columns; and WorkBeads chromatography resins. Its products are used in antibodies, his-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines applications. Bio-Works Technologies AB (publ) founded in 2006 and is headquartered in Uppsala, Sweden.
BIO-WORKS TECHN. AB management
1- Ms. Lone CarlbomChief Executive Officer